Portal de Periódicos da CAPES

AAD consensus statement on psoriasis therapies

2003; Elsevier BV; Volume: 49; Issue: 5 Linguagem: Inglês

10.1016/s0190-9622(03)01870-x

1097-6787

Jeffrey P. Callen, Gerald G. Krueger, Mark Lebwohl, Elizabeth I. McBurney, Philip J. Mease, Alan Menter, Amy S. Paller, David M. Pariser, Michael E. Weinblatt, Gail M. Zimmerman,

Dermatology and Skin Diseases

This statement was developed as part of the Psoriasis Therapies Educational Summit meeting that took place in Louisville, Kentucky, November 2 and 3, 2002. The statement was developed to fill the gap between the existing Guidelines of Care document that was developed by the American Academy of Dermatology (AAD) in 1991 and its formal revision that will be developed with the use of “evidence-based” methods over the next several years. It is to be used to guide evaluation and treatment plans for patients with psoriasis and psoriatic arthritis until a new “evidence-based set of guidelines” is published. This statement should be supplemented by some excellent publications that have been recently developed by the National Psoriasis Foundation, a co-sponsor of the Summit meeting (see Suggested readings at the end of this article). This statement was developed by a subset of the attendees, led by Gerald D. Weinstein, MD, and Craig A. Elmets, MD, and subsequently has been sent for review and comment to all Summit attendees, AAD members, and members of the Ad Hoc Task Force: Psoriasis Education Initiative and the Psoriasis Therapies Educational Summit Work Group.